151 related articles for article (PubMed ID: 33416007)
1. Association between Site-of-Care and the Cost and Modality of Radiotherapy for Prostate Cancer: Analysis of Medicare Beneficiaries from 2015 to 2017.
Tringale KR; Gennarelli RL; Gillespie EF; Mitchell AP; Zelefsky MJ
Cancer Invest; 2021 Feb; 39(2):144-152. PubMed ID: 33416007
[TBL] [Abstract][Full Text] [Related]
2. Survival outcomes of combined external beam radiotherapy and brachytherapy vs. brachytherapy alone for intermediate-risk prostate cancer patients using the National Cancer Data Base.
Amini A; Jones BL; Jackson MW; Rusthoven CG; Maroni P; Kavanagh BD; Raben D
Brachytherapy; 2016; 15(2):136-46. PubMed ID: 26825856
[TBL] [Abstract][Full Text] [Related]
3. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
4. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity.
Yu JB; Soulos PR; Herrin J; Cramer LD; Potosky AL; Roberts KB; Gross CP
J Natl Cancer Inst; 2013 Jan; 105(1):25-32. PubMed ID: 23243199
[TBL] [Abstract][Full Text] [Related]
5. A nationwide charge comparison of the principal treatments for early stage prostate carcinoma.
Brandeis J; Pashos CL; Henning JM; Litwin MS
Cancer; 2000 Oct; 89(8):1792-9. PubMed ID: 11042575
[TBL] [Abstract][Full Text] [Related]
6. The burden of overtreatment: comparison of toxicity between single and combined modality radiation therapy among low risk prostate cancer patients.
Jiang R; Tomaszewski JJ; Ward KC; Uzzo RG; Canter DJ
Can J Urol; 2015 Feb; 22(1):7648-55. PubMed ID: 25694014
[TBL] [Abstract][Full Text] [Related]
7. Cost implications of the rapid adoption of newer technologies for treating prostate cancer.
Nguyen PL; Gu X; Lipsitz SR; Choueiri TK; Choi WW; Lei Y; Hoffman KE; Hu JC
J Clin Oncol; 2011 Apr; 29(12):1517-24. PubMed ID: 21402604
[TBL] [Abstract][Full Text] [Related]
8. Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer.
Halpern JA; Sedrakyan A; Hsu WC; Mao J; Daskivich TJ; Nguyen PL; Golden EB; Kang J; Hu JC
Cancer; 2016 Aug; 122(16):2496-504. PubMed ID: 27224858
[TBL] [Abstract][Full Text] [Related]
9. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
[TBL] [Abstract][Full Text] [Related]
10. Risk of second cancers according to radiation therapy technique and modality in prostate cancer survivors.
Berrington de Gonzalez A; Wong J; Kleinerman R; Kim C; Morton L; Bekelman JE
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):295-302. PubMed ID: 25636756
[TBL] [Abstract][Full Text] [Related]
11. The decreased use of brachytherapy boost for intermediate and high-risk prostate cancer despite evidence supporting its effectiveness.
Orio PF; Nguyen PL; Buzurovic I; Cail DW; Chen YW
Brachytherapy; 2016; 15(6):701-706. PubMed ID: 27317191
[TBL] [Abstract][Full Text] [Related]
12. Additional treatments and reimbursement rates associated with prostate cancer treatment for patients undergoing radical prostatectomy, interstitial brachytherapy, and external beam radiotherapy.
Goharderakhshan RZ; Grossfeld GD; Kassis A; Shinohara K; Roach M; Carroll PR
Urology; 2000 Oct; 56(4):622-6. PubMed ID: 11018618
[TBL] [Abstract][Full Text] [Related]
13. The use of supplemental external beam radiotherapy in men with low-risk prostate cancer undergoing brachytherapy before and after the 1999 American Brachytherapy Society Guideline statement.
Cheung AK; Chen MH; Moran BJ; Braccioforte MH; Dosoretz DE; Salenius S; Katin M; Ross R; D'Amico AV
Brachytherapy; 2010; 9(2):145-50. PubMed ID: 20346894
[TBL] [Abstract][Full Text] [Related]
14. Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy.
Yang DD; Muralidhar V; Mahal BA; Nguyen PL; Devlin PM; King MT; Orio PF
Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):53-58. PubMed ID: 29254781
[TBL] [Abstract][Full Text] [Related]
15. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
Kishan AU; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Sandler KA; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Stephenson AJ; Klein EA; Song DY; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco S; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR
JAMA; 2018 Mar; 319(9):896-905. PubMed ID: 29509865
[TBL] [Abstract][Full Text] [Related]
16. Contemporary prostate cancer radiation therapy in the United States: Patterns of care and compliance with quality measures.
Lee DJ; Barocas DA; Zhao Z; Huang LC; Koyama T; Resnick MJ; Conwill R; McCollum D; Cooperberg MR; Goodman M; Greenfield S; Hamilton AS; Hashibe M; Kaplan SH; Paddock LE; Stroup AM; Wu XC; Penson DF; Hoffman KE
Pract Radiat Oncol; 2018; 8(5):307-316. PubMed ID: 30177030
[TBL] [Abstract][Full Text] [Related]
17. Management of Radiation Therapy Oncology Group grade 4 urinary adverse events after radiotherapy for prostate cancer.
Mayer EN; Tward JD; Bassett M; Lenherr SM; Hotaling JM; Brant WO; Lowrance WT; Myers JB
BJU Int; 2017 May; 119(5):700-708. PubMed ID: 27469289
[TBL] [Abstract][Full Text] [Related]
18. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
19. Survival Outcomes of Dose-Escalated External Beam Radiotherapy versus Combined Brachytherapy for Intermediate and High Risk Prostate Cancer Using the National Cancer Data Base.
Amini A; Jones B; Jackson MW; Yeh N; Waxweiler TV; Maroni P; Kavanagh BD; Raben D
J Urol; 2016 May; 195(5):1453-1458. PubMed ID: 26576709
[TBL] [Abstract][Full Text] [Related]
20. [How to select the treatment options in prostate cancer].
Karasawa K; Chang TC; Kuga G; Hanyu N; Yoshida D
Gan To Kagaku Ryoho; 2007 Jul; 34(7):1006-10. PubMed ID: 17637536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
